Yannik Schlup had an idea. He wanted to breed cannabis varieties that would revolutionize the cannabis industry. Thanks to his breeding experience, Yannik was aware that the best way to successfully realize his endeavor would be to target the plant’s building blocks – its DNA.
Fortunately, Yannik met Stevens Senn, who is the co-founder of Pure Production AG. Stevens played an integral role in paving the way for Yannik’s venture.
Together they approached Prof. Bruno Studer, head of molecular plant breeding at the Federal Institute of Technology (ETH), in Zurich. He advised them how they could employ the latest technological advancements to breed cannabis, resulting in the launch of Puregene AG.
The medicinal benefits of cannabis are globally publicized. Both Stevens and Yannik had first-hand experience of its healing potential in treating medical conditions. They recognized the value that cannabis would bring to society. Combining their experience and academic background, they initialized a research and development project to bring these promising compounds to market.
The Swiss market, with its relatively high THC limit of 1%, was welcoming pioneers like Yannik and Stevens. However, to maintain a competitive advantage in a high-price market like Switzerland, Puregene had to prove itself as a leading cannabis innovator.
They soon recognized the need for more specialists and recruited molecular breeder Dr. Michael Ruckle as well as biotechnologist Dr. Gavin George, both senior scientists from ETH Zurich. This expert team has been directing and maintaining Puregene’s pioneering role in the cannabis breeding industry for the past two years.
Puregene’s ever-growing team is at the frontier of discovering novel cannabis traits and developing new varieties unique to the world market.